A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Com… (NCT07502300) | Clinical Trial Compass
Not Yet RecruitingPhase 3
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
China562 participantsStarted 2026-04
Plain-language summary
This trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of BL-B01D1 in combination with tislelizumab versus platinum-based chemotherapy in combination with tislelizumab in first-line patients with extensive-stage small cell lung cancer.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Voluntarily sign the informed consent form and comply with the protocol requirements;
✓. Age ≥ 18 years;
✓. Expected survival time ≥ 3 months;
✓. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
✓. Patients with histopathologically and/or cytologically confirmed extensive-stage small cell lung cancer;
✓. Agree to provide archived tumor tissue specimens from the primary or metastatic lesions within 3 years, or fresh tissue samples;
✓. Must have at least one measurable lesion as defined by RECIST v1.1;
✓. Toxicity from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;